Ischemia
Drug research and approvals for ischemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 1,987 studies of ischemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 25 open orphan designations naming it.
- Recruiting worldwide: 1,987
- Trials authorized in Canada: 2
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting now
Newest start dates first, of 1,987 recruiting on ClinicalTrials.gov ↗- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,…NCT07083557 · Not reported · Bettina Mittendorfer · starts Jan 1, 2027
- Prognostic Value of Oxygen-15 Water PET in Coronary Artery DiseaseNCT07932314 · Phase 3 · Vastra Gotaland Region · starts Dec 1, 2026
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)NCT07916883 · Not reported · Washington University School of Medicine · starts Nov 18, 2026
- Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only…NCT07852689 · Not applicable · Korea University Guro Hospital · starts Nov 16, 2026
- Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic StrokeNCT07903922 · Not reported · Minyoul Baik · starts Nov 6, 2026
- Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass SurgeryNCT07898215 · Not reported · Adiyaman University · starts Nov 4, 2026
- Short-Term External Trigeminal Nerve Stimulation for Acute Ischemic StrokeNCT07911605 · Not applicable · Xidian University · starts Nov 3, 2026
- Perioperative Limb Oxygenation Monitoring in Patients With CLTINCT07931768 · Not applicable · Belarusian State Medical University · starts Nov 2, 2026
Drug pipeline
1 approved, 6 in phase 3, 8 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Clopidogrel
- Aspirin
- Phase 3 Cyclooxygenase inhibitor
- Paclitaxel
- Phase 3 Tubulin inhibitor
- Apixaban
- Phase 3 Coagulation factor X inhibitor
- Cangrelor
- Phase 3 Purinergic receptor P2Y12 antagonist
- Ixmyelocel-t
- Phase 3
- Emiplacel
- Phase 3
- Dexamethasone phosphoric acid
- Phase 2 Glucocorticoid receptor agonist
- Rivaroxaban
- Phase 2 Coagulation factor X inhibitor
- Temsirolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Rosuvastatin
- Phase 2 HMG-CoA reductase inhibitor
- Vepoloxamer
- Phase 2
- Moxaverine
- Phase 2
- Diethanolamine
- Phase 2
- Donaperminogene seltoplasmid
- Phase 2
- Enalapril
- Phase 1 Angiotensin-converting enzyme inhibitor
- Ticagrelor
- Phase 1 Purinergic receptor P2Y12 negative allosteric modulator
- Adenosine
- Phase 1 Adenosine receptor agonist
- Sodium nitrate
- Phase 1
- Acetylcholine
- Phase 1 Muscarinic acetylcholine receptor M3 agonist
- Oxygen
- Phase 1 Essential for cellular homeostasis
- Plasmalyte a
- Phase 1
- Edetate disodium anhydrous
- Early phase 1 Calcium chelating agent
How its trials ended
2,346 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 430 whose ending is known, 37% met their primary endpoint, 13% missed it and 50% stopped early.
- Completed, result not reported83636%
- Ongoing59125%
- Status unknown48921%
- Met its primary endpoint1607%
- Stopped: other or unclear1215%
- Missed its primary endpoint552%
- Stopped: enrollment or feasibility512%
- Stopped: sponsor or business decision201%
- Stopped: lack of efficacy151%
- Stopped: funding50%
- Stopped: safety30%
Trials authorized in Canada
Newest first; search them all in Canada trials| Dec 20, 2018 | "evaluation of prognostic value of 18f-fluoroazomycin arabinoside (FAZA)18F-FLUOROAZOMYCIN arabinoside (FAZA) | Centre for Probe Development and Commercialization | Ongoing |
| May 5, 2016 | Enhancing the anabolic effect of nutrition in critically ill patients by administering exogenous amino acidsAmino acids | Research Institute of The McGill University Health Centre | Pending |
FDA orphan designations
Approved first, then open designations, newest first; 15 of 26| Jun 25, 1992 | Lioresal IntrathecalManagement of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable… | Medtronic, Inc. | Approved |
| Nov 6, 2023 | AlprostadilPrevention of ischemia/reperfusion injury resulting from solid organ transplantation. | Institut Georges Lopez | Designated |
| May 31, 2023 | N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-ThrPrevention of ischemia/reperfusion injury in kidney transplantation | Young Therapeutics, LLC | Designated |
| Dec 14, 2022 | Ketamine hydrochloridePrevention of ischemia/reperfusion injury during solid organ transplantation. | PharmaTher Inc. | Designated |
| Oct 17, 2022 | Synthetic polymer PEG conjugated to a phospholipid anchor…Prevention of ischemia reperfusion injury during solid organ transplantation | iCoat Medical AB | Designated |
| Feb 15, 2022 | BucillaminePrevention of ischemia-reperfusion injury during liver transplantation | Revive Therapeutics Inc. | Designated |
| Apr 27, 2021 | DimethyltryptaminePrevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation. | Sairiyo Therapeutics Inc. | Designated |
| Jul 10, 2020 | MitochondriaPrevention of ischemia-reperfusion injury during solid organ transplantation | cellvie Inc. | Designated |
| Nov 5, 2018 | CannabidiolPrevention of ischemia/reperfusion Injury resulting from solid organ transplantation | Revive Therapeutics Ltd. | Designated |
| Aug 3, 2017 | PapaverineTreatment of mesenteric ischemia | RNR BioMedical Inc. | Designated |
| May 2, 2017 | Macromolecular conjugate of heparin sodium on a polymer…Prevention of ischemia-reperfusion injury associated with solid organ tranplantation | Corline Biomedical AB | Designated |
| Dec 31, 2015 | Adeno-associated viral vector expressing the human vascular…Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated | Integene International Holding, LLC | Designated |
| Oct 16, 2014 | Cardiotrophin-1Prevention of ischemia-reperfusion injury in kidney transplant recipients | Digna Biotech, S.L. | Designated |
| Nov 8, 2013 | Poloxamer 188Treatment of Acute Limb Ischemia | Mast Therapeutics Inc. | Designated |
| Aug 6, 2013 | Human HeminPrevention of ischemia reperfusion injury in patients undergoing solid organ transplantation | Borders Technology Management Ltd | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA